The purpose of the study is to determine how well lumateperone works in reducing the symptoms of mania over a period of three weeks. During this time, participants will take the medication daily and will be monitored by healthcare professionals. The study will compare the changes in symptoms from the beginning to the end of the three-week period to assess the medication’s impact.

The purpose of this study is to find out if melatonin can help improve mood stability in people with bipolar disorder and whether it can help prevent mood episodes from coming back. The study will also look at whether melatonin helps with symptoms of mania, which are the high-energy periods, or depression, which are the low-energy periods. The study will last for six months, during which participants will take either melatonin or placebo tablets by mouth. The maximum daily dose of melatonin used in the study will be 6 milligrams.

During the study, participants will track their daily mood changes using a digital monitoring system to measure mood stability. Other aspects of health will also be measured, including depression symptoms, sleep quality, mania symptoms, daily functioning, thinking abilities, and certain markers in blood, hair, and urine samples that can show levels of stress and inflammation in the body. These measurements will help researchers understand how well melatonin works compared to placebo in managing bipolar disorder.

Participants in the study will receive either the vitamin D supplement or a placebo. The trial will monitor changes in the severity of depression symptoms using a tool called the Montgomery-Asberg Depression Rating Scale (MADRS). The study will also track the time it takes for symptoms to improve significantly. Additionally, the study will measure changes in vitamin D levels in the body at both 12 and 24 weeks.

The goal of this research is to understand whether vitamin D supplementation can be an effective treatment option for people with depressive or bipolar disorders. By participating in this study, researchers hope to gather valuable information that could lead to better treatment strategies for these conditions in the future.

The purpose of the study is to evaluate how effective and safe Spravato is for patients with this type of depression. Participants in the study will use the nasal spray, and researchers will monitor their response to the treatment over a period of time. The study is designed to gather information on how well the medication works and to observe any side effects that may occur. This information will help determine if Spravato could be a viable treatment option for those who have not found relief with other medications.

Throughout the study, participants will be closely observed to ensure their safety and to track any changes in their symptoms. The study will also look at how well participants tolerate the medication, which means checking if they can continue using it without significant issues. The findings from this trial may lead to further research, including more extensive studies that compare Spravato to a placebo, to better understand its potential benefits and risks for people with treatment-resistant bipolar depression.

The study will last for a period of 14 days, during which participants will take the medication in the form of a hard capsule by mouth. The effects of the treatment will be monitored by assessing the severity of depression symptoms using a tool called the Hamilton Scale for Depression (HAMD-21). This assessment will be conducted several times throughout the study to track any changes in symptoms.

The purpose of this study is to determine if adding etifoxine hydrochloride to the usual treatment can speed up the improvement of depression symptoms compared to adding a placebo. Participants will be closely monitored for any changes in their condition and any side effects that may occur during the study period.

Participants in the study will receive either amiloride or a placebo and will be monitored over a period of time to assess changes in their condition. The study will last for several months, with key assessments occurring at 2, 6, and 12 months. During this time, researchers will evaluate various factors such as changes in urine concentration, the number of times participants need to urinate at night, their level of thirst, and overall quality of life. Additionally, the study will monitor kidney function and mood changes to ensure the safety and effectiveness of the treatment.

The trial aims to provide valuable insights into whether amiloride can be a beneficial treatment for managing nephrogenic diabetes insipidus in patients with bipolar disorder who are on long-term lithium therapy. By participating in this study, researchers hope to improve the understanding of how to better manage this condition and enhance the quality of life for affected individuals.

Participants in the study will be randomly assigned to receive either low-dose aspirin or a placebo, which is a substance with no active medication. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the aspirin or the placebo, ensuring unbiased results. The study will last for a total of 12 months, with regular check-ins to monitor the participants’ progress and any changes in their condition.

The main goal is to see if adding low-dose aspirin can help improve symptoms of depression in bipolar disorder and prevent future episodes. The study will also look at the overall safety of using aspirin in this way. Participants will be assessed using various scales to measure their mood and general functioning throughout the study period. This research could provide valuable insights into new ways to manage bipolar disorder effectively.

Participants in the study will receive either lithium or cariprazine, both of which are taken orally. The study will last for a period of eight weeks, during which the effects of the treatments will be monitored and compared. The effectiveness of the treatments will be assessed using a scale that measures changes in depression symptoms. This will help researchers understand how each medication impacts the condition and which might be more beneficial for patients experiencing a depressive episode in bipolar disorder.

Throughout the study, participants will be regularly evaluated to track their progress and any changes in their condition. The study aims to provide valuable insights into the treatment of bipolar depression, potentially leading to improved management strategies for those affected by this challenging condition.

Participants in the study will be randomly assigned to receive either Memantine or a placebo, which is a substance with no active medication. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving Memantine and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will last for up to 52 weeks, during which the participants’ symptoms and any side effects will be closely monitored.

The main goal of the study is to see if Memantine can help reduce the manic symptoms in adolescents with Bipolar Disorder. The researchers will also look at how long participants stay in the study without needing additional medication and whether there are any improvements in their overall condition over the course of the study. Safety and any potential side effects will be carefully recorded to ensure the well-being of all participants.

The purpose of the study is to evaluate how effective and safe lumateperone is in treating manic episodes associated with Bipolar I Disorder. Participants will be randomly assigned to receive either lumateperone or a placebo for a period of three weeks. During this time, the study will monitor changes in the participants’ symptoms to determine the impact of the treatment.

Throughout the study, participants will be closely observed to ensure their safety and to assess any changes in their condition. The goal is to gather information that could help improve treatment options for those experiencing manic episodes due to Bipolar I Disorder.

Participants in the study will be randomly assigned to receive either lithium carbonate or lamotrigine. The study will last for six months, during which the effects of the medications on mood stabilization and other important health outcomes will be observed. The trial aims to determine whether lithium carbonate is more effective than lamotrigine in improving mood stability and preventing relapses into depressive or hypomanic states.

Throughout the study, participants will take the medication in tablet form by mouth. The trial is designed to be single-blinded, meaning that the participants will not know which medication they are receiving. The study will also include a placebo group to help compare the effects of the medications. The results will help to better understand the benefits and potential side effects of these treatments for managing bipolar disorder, type II.

Participants in the study will receive either the intensified treatment or the usual treatment for a period of six weeks. The purpose of the study is to observe changes in the severity of depression symptoms and overall treatment response. The study will also monitor any side effects and changes in quality of life. The intensified treatment involves adjusting the medication regimen to better address the symptoms of bipolar depression, while the usual treatment follows standard practices.

The study will help determine if the intensified treatment is more effective than the usual treatment for individuals experiencing their first treatment failure. This information could be valuable in improving treatment strategies for bipolar depression in the future. Participants will be closely monitored throughout the study to ensure their safety and well-being. The study does not involve any invasive procedures, and all medications will be taken orally.

Participants in this study will have previously taken part in a related research study that compared the short-term effects of pramipexole with a placebo. Those who were initially given pramipexole and wish to continue their treatment, as well as those who received a placebo and meet certain criteria, can join this follow-up study. The study will last for a maximum of 25 weeks, during which participants will continue to take pramipexole and be monitored for its effects on their symptoms of depression.

Throughout the study, various aspects of the participants’ health and well-being will be assessed, including their overall mood, physical activity levels, sleep patterns, and any side effects they may experience. The study aims to gather comprehensive data to better understand how pramipexole can help improve symptoms of anhedonic depression and to ensure that it is a safe and effective treatment option for long-term use.

The purpose of the study is to see if an early-intensified treatment can improve symptoms more effectively than the standard approach. Participants will be randomly assigned to receive either the intensified treatment or the usual treatment. The study will last for four to six weeks, depending on the specific condition being treated. During this time, participants will receive their assigned treatment and have their symptoms monitored to assess any changes in severity.

This trial is designed for individuals who have experienced a first-time failure with their initial treatment for schizophrenia, major depressive disorder, or bipolar depression. The goal is to determine if a more aggressive treatment approach can lead to better outcomes for these patients. Participants will be closely monitored throughout the study to ensure their safety and to evaluate the effectiveness of the treatments being tested.

During the study, participants will take OSU6162 tablets daily for up to 8 weeks while continuing their current mood stabilizer medication. The maximum daily dose of the study medication will be 135 mg. Patients will need to stay in a psychiatric ward during the study period. The medication will be given in flexible doses, which means the amount can be adjusted based on individual patient response.

Throughout the study period, healthcare providers will monitor patients’ depression symptoms using standardized rating scales. They will track any changes in depression severity and observe how participants respond to the treatment. Regular check-ups will be conducted to ensure patient safety and to evaluate the medication’s effects.